Interaction of tau with HNRNPA2B1 and N ⁶ -methyladenosine RNA mediates the progression of tauopathy.

Autor: Jiang L; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA., Lin W; Center for Network Systems Biology, Boston University School of Medicine, Boston, MA 02118, USA., Zhang C; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA., Ash PEA; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA., Verma M; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA., Kwan J; Center for Network Systems Biology, Boston University School of Medicine, Boston, MA 02118, USA., van Vliet E; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA., Yang Z; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA., Cruz AL; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA., Boudeau S; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA., Maziuk BF; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA., Lei S; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA., Song J; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA., Alvarez VE; Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA., Hovde S; Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA., Abisambra JF; Department of Neuroscience, University of Florida, Gainesville, FL 32611, USA., Kuo MH; Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA., Kanaan N; Department of Translational Science and Molecular Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA., Murray ME; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA., Crary JF; Department of Pathology, Mount Sinai Medical Center, New York, NY 10029, USA., Zhao J; Department of Electrical and Computer Engineering, Boston University, Boston, MA 02459, USA., Cheng JX; Department of Electrical and Computer Engineering, Boston University, Boston, MA 02459, USA., Petrucelli L; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA., Li H; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA., Emili A; Center for Network Systems Biology, Boston University School of Medicine, Boston, MA 02118, USA., Wolozin B; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA; Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA; Center for Neurophotonics, Boston University, Boston, MA 02215, USA; Center for Systems Neuroscience, Boston University, Boston, MA 02215, USA. Electronic address: bwolozin@bu.edu.

Publikováno v: Molecular cell [Mol Cell] 2021 Oct 21; Vol. 81 (20), pp. 4209-4227.e12. Date of Electronic Publication: 2021 Aug 27.

Changes in neuronal immunofluorescence in the C- versus N-terminal domains of hnRNP H following D1 dopamine receptor activation.

Autor: Ruan QT; Laboratory of Addiction Genetics, Department of Pharmacology and Experimental Therapeutics and Psychiatry, Boston University School of Medicine, United States; Biomolecular Pharmacology Training Program, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, United States; Transformative Training Program in Addiction Science, Boston University, United States., Yazdani N; Laboratory of Addiction Genetics, Department of Pharmacology and Experimental Therapeutics and Psychiatry, Boston University School of Medicine, United States; Biomolecular Pharmacology Training Program, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, United States; Transformative Training Program in Addiction Science, Boston University, United States., Beierle JA; Laboratory of Addiction Genetics, Department of Pharmacology and Experimental Therapeutics and Psychiatry, Boston University School of Medicine, United States; Biomolecular Pharmacology Training Program, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, United States; Transformative Training Program in Addiction Science, Boston University, United States., Hixson KM; Biomolecular Pharmacology Training Program, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, United States; Laboratory of Translational Epilepsy, Department of Pharmacology and Experimental Therapeutics and Biology, Boston University School of Medicine, United States., Hokenson KE; Biomolecular Pharmacology Training Program, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, United States; Laboratory of Translational Epilepsy, Department of Pharmacology and Experimental Therapeutics and Biology, Boston University School of Medicine, United States., Apicco DJ; Laboratory of Addiction Genetics, Department of Pharmacology and Experimental Therapeutics and Psychiatry, Boston University School of Medicine, United States; Laboratory of Neurodegeneration, Department of Pharmacology and Experimental Therapeutics and Neurology, Boston University School of Medicine, United States., Luttik KP; Laboratory of Addiction Genetics, Department of Pharmacology and Experimental Therapeutics and Psychiatry, Boston University School of Medicine, United States., Zheng K; Laboratory of Addiction Genetics, Department of Pharmacology and Experimental Therapeutics and Psychiatry, Boston University School of Medicine, United States., Maziuk BF; Laboratory of Neurodegeneration, Department of Pharmacology and Experimental Therapeutics and Neurology, Boston University School of Medicine, United States., Ash PEA; Laboratory of Neurodegeneration, Department of Pharmacology and Experimental Therapeutics and Neurology, Boston University School of Medicine, United States., Szumlinski KK; Department of Psychological and Brain Sciences, University of California, Santa Barbara, United States., Russek SJ; Laboratory of Translational Epilepsy, Department of Pharmacology and Experimental Therapeutics and Biology, Boston University School of Medicine, United States., Wolozin B; Laboratory of Neurodegeneration, Department of Pharmacology and Experimental Therapeutics and Neurology, Boston University School of Medicine, United States., Bryant CD; Laboratory of Addiction Genetics, Department of Pharmacology and Experimental Therapeutics and Psychiatry, Boston University School of Medicine, United States. Electronic address: camron@bu.edu.

Publikováno v: Neuroscience letters [Neurosci Lett] 2018 Sep 25; Vol. 684, pp. 109-114. Date of Electronic Publication: 2018 Jul 09.

RNA binding proteins co-localize with small tau inclusions in tauopathy.

Autor: Maziuk BF; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA., Apicco DJ; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA., Cruz AL; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA., Jiang L; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA., Ash PEA; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA., da Rocha EL; Mayo Clinic, Rochester, MN, USA., Zhang C; Mayo Clinic, Rochester, MN, USA., Yu WH; Department of Pathology and Cell Biology, Taub Institute for Alzheimer's Disease Research, Columbia University Medical Center, New York, NY, USA., Leszyk J; University of Massachusetts Medical Center, Worcester, MA, USA., Abisambra JF; Sanders-Brown Center on Aging, Department of Physiology, Spinal Cord and Brain Injury Research Center, and Epilepsy Center, University of Kentucky, Lexington, KY, USA., Li H; Mayo Clinic, Rochester, MN, USA., Wolozin B; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA. bwolozin@bu.edu.; Department of Neurology, Boston University School of Medicine, Boston, MA, USA. bwolozin@bu.edu.; Department of Pharmacology and Neurology Program in Neuroscience, Boston University School of Medicine, 72 East Concord St., R614, Boston, MA, 02118-2526, USA. bwolozin@bu.edu.

Publikováno v: Acta neuropathologica communications [Acta Neuropathol Commun] 2018 Aug 01; Vol. 6 (1), pp. 71. Date of Electronic Publication: 2018 Aug 01.